呼和浩特附近的人想找个玩一玩-呼和浩特附近的人想找个玩一玩_首页

在临沧酒店晚上怎么叫服务

Welcome to the official website of Yantai Dongcheng Pharmaceutical Group Co., Ltd!
Stock Code: 002675
media coverage
Your current position: home page >> News Center >> media coverage
Joint efforts of general medical, nuclear drug aircraft carrier two wheel drive
Date [June 15, 2018 11:06]【 】Times

Dongcheng pharmaceutical, the aircraft carrier of nuclear medicine industry, has made new moves.

 

Andico, the acquisition target of Dongcheng pharmaceutical, signed an agreement with General Electric Medical Co., Ltd. (hereinafter referred to as "general medical" or "GEHC") to exclusively distribute Metatron (strontium chloride [89Sr] injection) in mainland China, and officially started the relevant sales work. Metatron is a radionuclide drug developed by GE company to relieve bone pain caused by bone metastasis of advanced malignant tumors such as prostate cancer and breast cancer.

 

This is the first time that Dongcheng Pharmaceutical Co., Ltd., a listed company, cooperates with a large international pharmaceutical company in the field of nuclear medicine, with a view to bringing high-quality foreign nuclear drug products into China and benefiting the majority of cancer patients. This will enrich the business types of nuclide medicine products and the product line of nuclide preparations, and help to strengthen the product layout of the company in the field of therapeutic nuclides. Dongcheng pharmaceutical will also start the expert consensus work of strontium chloride [89Sr] injection in the analgesic treatment of tumor bone metastasis in China, so as to standardize the clinical use of the drug in China.

 

Prospect of palliative therapy with radionuclide

 

As one of the most effective methods and means for the treatment of bone metastases of tumor, injectable radionuclide therapy is a treatment method that uses the biological effect of beta particles produced in the process of nuclide decay to inhibit or destroy the diseased tissue. It is a treatment option for bone pain and pain relief. It can aim at multiple bone metastases in the whole body and greatly relieve the pain of patients.

   

In fact, in recent years, with the high incidence of tumor, the incidence of bone metastasis of advanced malignant tumor is as high as 15% ~ 70%, and the incidence of pathological fracture in one year of patients with bone metastasis is 22% ~ 52%. Pain, fracture and dysfunction associated with bone metastasis seriously affect the quality of life of cancer patients. Clinical experts predict that radionuclide therapy will be more and more widely used in such patients.

 

Strontium chloride [89Sr] injection is one of the representative drugs in radionuclide treatment of bone metastasis.


Compared with the domestic radionuclide drug 153Sm EDTMP, strontium chloride has four advantages: first, the side effects are slight and the inhibition of hemogram is rare; second, the analgesic effect lasts for a long time, generally up to 3-6 months; third, the total effective rate is higher; fourth, it has no radiation effect on the surrounding environment.


Clinical experts also pointed out that compared with the traditional opioid analgesics, due to the exact curative effect, less side effects and direct treatment for tumors, radionuclide therapy such as strontium chloride [89Sr] can not only effectively relieve the pain symptoms, but also reduce the dosage of analgesic.


In addition, strontium chloride [89Sr] injection in the treatment of bone metastases pain is simple, intravenous injection can be, after injection, pain relief occurs in about two weeks, the curative effect can be maintained for 3 to 6 months.

 

In terms of the development process of global radionuclide drugs, radium chloride, a radionuclide drug for prostate cancer treatment, came into the market in 2013, and its rapid volume indicates that the global radionuclide drugs have entered a period of rapid growth.

 

In recent years, the prices of Sr-89, MO-99 and I-131 have increased except for co-60-f-18, especially due to the decommissioning of some foreign reactors and the increasing demand for downstream drug preparation, the prices of MO-99 and Sr-89, I-131 and I-125 have increased significantly.

 

Therefore, industry insiders believe that the cooperation between Andico and Ge can effectively reduce the risk of domestic preparation supply of strontium chloride [89Sr].

 

Innovation mode of "independent R & D + external introduction"

 

"Innovation is the soul of enterprise development".

 

In recent years, Dongcheng pharmaceutical, with nuclear medicine as its core competitiveness, has been rapidly integrating China's nuclear drug market. Under the leadership of global nuclear medicine leaders, Dongcheng pharmaceutical is laying out international nuclear medicine cutting-edge technologies, launching research and development of key innovative products. A number of class 1.1 radionuclide targeted new drugs independently developed will come out in the next few years.

 

The cooperation between Dongcheng pharmaceutical and Ge is also regarded as a positive attempt to open international innovation cooperation in the field of nuclear medicine. Dongcheng pharmaceutical will take this opportunity to introduce more innovative nuclear medicine products into the Chinese market through the "independent research and development + external introduction" double wheel drive mode, so as to bring innovative nuclear medical solutions for Chinese patients.

 

According to the Research Report of "military civilian integration of nuclear industry - nuclear medicine" published on snowball, Dongcheng Pharmaceutical Co., Ltd. acquired Chengdu Yunke Pharmaceutical Co., Ltd. in 2016, becoming the first domestic nuclide drug to enter the capital market. Since then, the nuclear medicine fund has been established to lay emphasis on the nuclear medicine industry.

 

On April 4, 2018, Dongcheng pharmaceutical completed the acquisition of Nanjing Jiangyuan Andico positron research and Development Co., Ltd. After the acquisition of Chengdu Yunke pharmaceutical and Dongcheng Xinke, the merger and integration of nuclear medicine has been further.

 

After years of operation and accumulation, Dongcheng pharmaceutical has built a very solid and competitive platform. Therefore, in addition to independent research and development, Dongcheng pharmaceutical also has the qualification and ability to build nests and attract Phoenix. Many nuclear pharmaceutical giants have also extended olive branches of international cooperation to Dongcheng pharmaceutical.

 

In this regard, securities companies believe that from the perspective of products, Dongcheng pharmaceutical has a complete product line of radionuclide drugs, stable growth of existing products (Yunke injection, fluorine [18F] - FDG) + approval of heavy varieties under research (rhenium [188Re] - HEDP injection, fluorine [18F] - AV45) + extension merger and acquisition, which can ensure the product echelon of nuclide drugs; from the perspective of channels, Andico + Dongcheng Xinke of Dongcheng Pharmaceutical Co., Ltd. integrated and improved nuclear drugs Room profitability, gradually build nuclear pharmacy network control terminal covering the whole country.

 

Rich product echelon and extensive marketing channels will promote the company's radionuclide drug business to maintain rapid growth, with the potential to develop into a national nuclear drug leader.

 

Last article:
Next:
contact us CONTACT US
0535-6391521
Switchboard: 86-535-6391521 / 6391522
Email: zxu @ midatlanticlegends.com
Address: No.7 Changbaishan Road, Yantai Development Zone, Shandong Province
Copyright 2014 Yantai Dongcheng Pharmaceutical Group Co., Ltd. All Rights Reserved Lu ICP Bei 18035060-1